Pancreatic cancer organoid
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB70522 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
| PRJNA473874 | ENA
Project description:Organoid sensitivity correlates with therapeutic resonsein patients with pancreatic cancer
| PRJNA777618 | ENA
Project description:Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
| PRJNA473873 | ENA
Project description:<p>We generated a collection of patient-derived pancreatic normal and cancer organoids. We performed whole genome sequencing, targeted exome sequencing, and RNA sequencing on organoids as well as matched tumor and normal tissue if available. This dataset is a valuable resource for pancreas cancer researchers, and those looking to compare primary tissue to organoid culture. In our linked publication, we show that pancreatic cancer organoids recapitulate the mutational spectrum of pancreatic cancer. Furthermore, RNA sequencing of organoids demonstrates the presence of both transcriptional subtypes of pancreas cancer.</p>
| phs001611 | dbGaP
Project description:Organoids from KPC pancreatic tumor tissue was treated with growth medium or conditional medium of mast cells treated with WT or BAG6 KO EVS of Pan02.
2024-12-31 | E-MTAB-13570 | biostudies-arrayexpress
Project description:The role of protein turnover in pancreatic ductal adenocarcinoma (PDA) metastasis has not previously been investigated. We introduce dynamic Stable-Isotope Labeling of Organoids (dSILO): a dynamic SILAC derivative that combines a pulse of isotopically labeled amino acids with isobaric tandem-mass tag (TMT) labeling to measure proteome-wide protein turnover rates in organoid systems.
2023-07-21 | MSV000092498 | MassIVE
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with only about 12 % of a 5-year survival rate. PDAC generally shows strong chemoresistance, which has been correlated with the tumor microenvironment (TME) of PDAC consisting of various types of stromal cells. Recent single-cell RNA sequence (scRNAseq) analyses demonstrate that a high percentage of myeloid cells in TME stroma cells is related to poor prognosis, and, among myeloid cells, tumor associated macrophages (TAM) are the most abundant population. However, their functions in PDAC malignancy remain largely unknown. Previously, we established a PDAC-organoid associated with an artificial TME by co-culturing patient-derived cancer cells, human induced pluripotent stem cell (hiPSC) derived mesenchymal and endothelial cells, which is called fused pancreatic cancer organoid (FPCO). Here, we further incorporated macrophages into FPCO and named it M0-FPCO. After 1 week of organoid culture, the macrophages in M0-FPCO expressed the conventional markers of M2-macrophages, such as CD163 and CD206. However, bulk RNAseq analysis showed that macrophages in M0-FPCO (FPCO-Mac) have distinct characteristics as compared with M2-macrophages induced with IL4 and 13. scRNAseq of M0-FPCO further demonstrated that FPCO-Mac was divided into 6 populations including Granulin+-TAM and SPP1+-TAM, which had been identified in human PDAC tissue. Furthermore, the number of PDAC cells was reduced in FPCO but not in M0-FPCO between 1 and 2 weeks of organoid culture, suggesting that cancer cells could survive longer or are protected from cell death in the presence of TAM. Moreover, the bulk-RNAseq analysis of the surviving M0-FPCO unveiled a GALE potentially associated with a worse prognosis in PDAC patients. Our novel PADC organoid including macrophage (M0-FPCO) replicated the PDAC-TAM features and elucidated their protumorigenic function.
2024-12-01 | GSE249672 | GEO
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with only about 12 % of a 5-year survival rate. PDAC generally shows strong chemoresistance, which has been correlated with the tumor microenvironment (TME) of PDAC consisting of various types of stromal cells. Recent single-cell RNA sequence (scRNAseq) analyses demonstrate that a high percentage of myeloid cells in TME stroma cells is related to poor prognosis, and, among myeloid cells, tumor associated macrophages (TAM) are the most abundant population. However, their functions in PDAC malignancy remain largely unknown. Previously, we established a PDAC-organoid associated with an artificial TME by co-culturing patient-derived cancer cells, human induced pluripotent stem cell (hiPSC) derived mesenchymal and endothelial cells, which is called fused pancreatic cancer organoid (FPCO). Here, we further incorporated macrophages into FPCO and named it M0-FPCO. After 1 week of organoid culture, the macrophages in M0-FPCO expressed the conventional markers of M2-macrophages, such as CD163 and CD206. However, bulk RNAseq analysis showed that macrophages in M0-FPCO (FPCO-Mac) have distinct characteristics as compared with M2-macrophages induced with IL4 and 13. scRNAseq of M0-FPCO further demonstrated that FPCO-Mac was divided into 6 populations including Granulin+-TAM and SPP1+-TAM, which had been identified in human PDAC tissue. Furthermore, the number of PDAC cells was reduced in FPCO but not in M0-FPCO between 1 and 2 weeks of organoid culture, suggesting that cancer cells could survive longer or are protected from cell death in the presence of TAM. Moreover, the bulk-RNAseq analysis of the surviving M0-FPCO unveiled a GALE potentially associated with a worse prognosis in PDAC patients. Our novel PADC organoid including macrophage (M0-FPCO) replicated the PDAC-TAM features and elucidated their protumorigenic function.
2024-12-01 | GSE249670 | GEO